PRQR
NASDAQProQR Therapeutics N.V.
Price$1.50-0.18 (-10.42%)
2026-03-042026-06-05
News · 26 weeks38-62%
2025-12-142026-06-07
Mix3190d
- Insider12(39%)
- Other9(29%)
- SEC Filings9(29%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Hinsch Gylvin Lykke4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hinsch Gylvin Lykke3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces First Quarter 2026 Operating and Financial ResultsAX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalystsContinued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory BoardEnded Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives throu
- PRProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformLEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced presentations at several upcoming scientific conferences, highlighting continued progress in the application of its Axiomer RNA editing platform. "These presentations collectively expand the body of evidence supporting the potential of our Axiomer RNA editing platform to enable precise RNA editing across multiple targets," said Gerard Platenburg, Co-founder and Chief Scientific Officer of ProQR. "Acro
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands. All relevant documents and information for the meeting, including the notice and agenda and explanatory notes, are or will be made available in the "Investors & Media" section of ProQR's website (www.proqr.com) under
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsLEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors. "We are pleased to nominate Lykke to our Board of Directors," said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. "Her extensive experience in global drug development and broad perspective across therapeutic areas will complement t
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventAX-0810 clinical target engagement data in healthy volunteers on track for this quarter; biliary atresia selected as initial Phase 2 indicationAdditional programs advancing toward the clinic, including AX-0811 and AX-0422Axiomer platform supporting multiple additional clinical data readouts within current runway LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its virtual Investor and Analyst event hosted today. During the event, ProQR prov
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders from industry and academiaProQR's first AI-discovered Development Candidate expected to enter the clinic in 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI strategy to enhance discovery on the Axiomer platform, including a partnership with Ginkgo Bioworks
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will host a virtual Investor and Analyst Event highlighting its pipeline entitled: "Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810" Ahead of the anticipated target engagement data for AX-0810 in the first half of 2026, the Company will showcase ProQR's broader RNA editing pipeline at this event, announce new programs that will have clinical data readouts in the runway, and unveil the primar
- INSIDERSEC Form 3 filed by new insider Valerio Domenico3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Platenburg Gerardus Johannes3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Maier Martin Alexander3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lawton Alison Frances3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hom Dennis3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Heggie Theresa3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Filius Bart3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider De Boer Daniel Anton3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
PRQR FAQ
7 questionsWhat does ProQR Therapeutics N.V. do?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial...Where does PRQR stock trade?
ProQR Therapeutics N.V. (PRQR) is listed on NASDAQ.What sector and industry is PRQR in?
ProQR Therapeutics N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ProQR Therapeutics N.V. go public?
ProQR Therapeutics N.V. (PRQR) completed its IPO in 2014.What are analysts saying about PRQR?
ProQR Therapeutics N.V. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $900.00 price target on 2026-03-12.What companies are similar to PRQR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PRQR side-by-side with any of them on Quantisnow.How can I track PRQR on Quantisnow?
Quantisnow aggregates ProQR Therapeutics N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRQR to receive live email and push alerts on every new disclosure.